In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price target of $78.00.
Ritu Baral’s rating is based on the strategic vision and leadership of Avidity Biosciences’ CEO, Sarah Boyce, who emphasizes a patient-centered approach in drug discovery. Boyce’s commitment to impacting patient lives and her recognition as one of the ‘Fiercest Women in Life Sciences’ highlight her capability to drive the company’s mission forward.
Additionally, Avidity Biosciences’ focus on integrating patient advocacy and market access into their strategic plan is seen as a strong foundation for future growth. These elements collectively contribute to Ritu Baral’s confidence in the company’s potential, leading to a Buy rating for Avidity Biosciences’ stock.
Baral covers the Healthcare sector, focusing on stocks such as Insmed, Sarepta Therapeutics, and Alnylam Pharma. According to TipRanks, Baral has an average return of 9.1% and a 45.89% success rate on recommended stocks.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $70.00 price target.